These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 12809960)

  • 1. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
    Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
    Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
    Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
    Olsson AG; Pauciullo P; Soska V; Luley C; Pieters RE; Broda G; Palacios B;
    Clin Ther; 2001 Jan; 23(1):45-61. PubMed ID: 11219479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
    Nakou ES; Filippatos TD; Georgoula M; Kiortsis DN; Tselepis AD; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2008 Jul; 24(7):1919-29. PubMed ID: 18513463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
    Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orlistat use in overweight women with mild hypercholesterolemia.
    Petrogiannopoulos C; Kalogeropoulos S; Latsios GS; Hartzoulakis G; Kalogeropoulos G; Zaharof A
    Int J Clin Pharmacol Res; 2002; 22(3-4):85-8. PubMed ID: 12837045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
    Ballantyne CM; Pazzucconi F; Pintó X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT
    Clin Ther; 2001 Feb; 23(2):177-92. PubMed ID: 11293552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.